The role of iron in neurodegenerative disorders: insights and opportunities with synchrotron light. Collingwood Joanna Frances, Davidson Mark Rogers, Front. Pharmacol., 19 August 2014 | doi: 10.3389/fphar.2014.00191
FULL TEXT PDF
Saturday, August 23, 2014
Friday, August 22, 2014
Preimplantation genetic diagnosis for inherited neurological disorders
Preimplantation genetic diagnosis for inherited neurological disorders. Ilan Tur-Kaspa, Roohi Jeelani
& P. Murali Doraiswamy, Nature Reviews Neurology 10, 417–424 (2014), doi:10.1038/nrneurol.2014.84
Preimplantation genetic diagnosis (PGD) is an option for couples at risk of having offspring with an inherited debilitating or fatal neurological disorder who wish to conceive a healthy child.
& P. Murali Doraiswamy, Nature Reviews Neurology 10, 417–424 (2014), doi:10.1038/nrneurol.2014.84
Preimplantation genetic diagnosis (PGD) is an option for couples at risk of having offspring with an inherited debilitating or fatal neurological disorder who wish to conceive a healthy child.
The influence of the European paediatric regulation on marketing authorisation of orphan drugs for children
The influence of the European paediatric regulation on marketing authorisation of orphan drugs for children. Annemarie Rosan Kreeftmeijer-Vegter, Anthonius de Boer, Roselinda H van der Vlugt-Meijer and Peter J de Vries; Orphanet Journal of Rare Diseases 2014, 9:120 doi:10.1186/s13023-014-0120-x
OPEN ACCESS; FULL TEXT PDF
OPEN ACCESS; FULL TEXT PDF
Wednesday, August 13, 2014
STATegics has identified CNS-available small molecule erythropoietin (EPO) Allomimetics that selectively activate the tissue-protective EPO receptor
STATegics has identified CNS-available small molecule erythropoietin (EPO) Allomimetics that selectively activate the
tissue-protective EPO receptor .
The compounds also demonstrate a favorable safety profile and penetrance to the brain at pharmacologically relevant concentrations, and are being investigated for treatment of PD, Friedreich’s ataxia, and acute kidney injury.
tissue-protective EPO receptor .
The compounds also demonstrate a favorable safety profile and penetrance to the brain at pharmacologically relevant concentrations, and are being investigated for treatment of PD, Friedreich’s ataxia, and acute kidney injury.
Tuesday, August 12, 2014
Electrochemical impedance sensor based on small molecule modified Au electrode for the recognition of a trinucleotide repeats
Electrochemical impedance sensor based on small molecule modified Au electrode for the recognition of a trinucleotide repeats .
Hanping He, Xiaoqian Peng, Min Huang, Gang Chang, Xiuhua Zhang and Shengfu Wang; Analyst, 2014, Accepted Manuscript,
DOI: 10.1039/C4AN00853G; Received 12 May 2014, Accepted 10 Aug 2014
The electrochemical impedance sensor provides the simple and rapid method to detect trinucleotide repeats without requiring labelling and immobilizations of DNA, making it promising for the early diagnosis of the neurodegenerative diseases
Hanping He, Xiaoqian Peng, Min Huang, Gang Chang, Xiuhua Zhang and Shengfu Wang; Analyst, 2014, Accepted Manuscript,
DOI: 10.1039/C4AN00853G; Received 12 May 2014, Accepted 10 Aug 2014
The electrochemical impedance sensor provides the simple and rapid method to detect trinucleotide repeats without requiring labelling and immobilizations of DNA, making it promising for the early diagnosis of the neurodegenerative diseases
Deferiprone in Friedreich’s Ataxia: A six-month randomized controlled trial
Deferiprone in Friedreich’s Ataxia: A six-month randomized controlled trial. Massimo Pandolfo, Javier Arpa, Martin B. Delatycki, Kim Hanh Le Quan Sang, Caterina Mariotti, Arnold Munnich, Irene Sanz-Gallego, Geneieve Tai, Mark A. Tarnopolsky, Franco Taroni, Michael Spino and Fernando Tricta; Annals of Neurology, DOI: 10.1002/ana.24248. Accepted manuscript online: 11 AUG 2014 09:41AM EST | DOI: 10.1002/ana.24248
A study of up to 12 years of follow-up of Friedreich ataxia utilising four measurement tools
A study of up to 12 years of follow-up of Friedreich ataxia utilising four measurement tools. Geneieve Tai, Louise A Corben, Lyle Gurrin, Eppie M Yiu, Andrew Churchyard, Michael Fahey, Brian Hoare, Sharon Downie, Martin B Delatycki; J Neurol Neurosurg Psychiatry jnnp-2014-308022Published Online First: 11 August 2014 doi:10.1136/jnnp-2014-308022
Epigenetic promoter silencing in Friedreich ataxia is dependent on repeat length
Epigenetic promoter silencing in Friedreich ataxia is dependent on repeat length. Yogesh K. Chutake, Christina Lam, Whitney N. Costello, Michael Anderson and Sanjay I. Bidichandani; Ann Neurol. http://dx.doi.org/10.1002/ana.24249; 2014
Dyclonine rescues frataxin deficiency in animal models and buccal cells of patients with Friedreich's Ataxia
Dyclonine rescues frataxin deficiency in animal models and buccal cells of patients with Friedreich's Ataxia. Sunil Sahdeo, Brian Scott, Marissa McMackin, Mittal Jasoliya, Brandon Brown2, Heike Wulff, Sue Perlman, Mark Pook and Gino Cortopassi; Hum. Mol. Genet. (2014) doi: 10.1093/hmg/ddu408 First published online: August 11, 2014
Full text PDF
Full text PDF
Monitoring mood states in everyday life: A new device for patients with cerebellar ataxia
Monitoring mood states in everyday life: A new device for patients with cerebellar ataxia, Silvia Clausi, Fabio Aloise, Maria P. Contento, Luigi Pizzamiglio, Marco Molinari, Maria Leggio; Psychiatry Research, Available online 1 August 2014, ISSN 0165-1781, http://dx.doi.org/10.1016/j.psychres.2014.07.051.
The preliminary data underscore the necessity to implement specific instruments to examine mood disorders in neurological patients. The MoMo device may be extremely valuable in clinical practice, allowing physicians to evaluate daily and weekly mood fluctuations during rehabilitation, pharmacological therapy, and psychotherapy, particularly in neurological patients.
The preliminary data underscore the necessity to implement specific instruments to examine mood disorders in neurological patients. The MoMo device may be extremely valuable in clinical practice, allowing physicians to evaluate daily and weekly mood fluctuations during rehabilitation, pharmacological therapy, and psychotherapy, particularly in neurological patients.
Subscribe to:
Posts (Atom)
